PKO Investment Management Joint Stock Co Acquires New Shares in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

PKO Investment Management Joint Stock Co bought a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 2,800 shares of the company's stock, valued at approximately $1,158,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. United Capital Financial Advisors LLC grew its stake in IDEXX Laboratories by 0.9% in the fourth quarter. United Capital Financial Advisors LLC now owns 2,446 shares of the company's stock worth $1,011,000 after purchasing an additional 22 shares in the last quarter. Gabelli Funds LLC lifted its holdings in IDEXX Laboratories by 5.3% in the fourth quarter. Gabelli Funds LLC now owns 500 shares of the company's stock worth $207,000 after acquiring an additional 25 shares during the last quarter. Perigon Wealth Management LLC lifted its holdings in IDEXX Laboratories by 1.8% in the fourth quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company's stock worth $632,000 after acquiring an additional 26 shares during the last quarter. Summit Trail Advisors LLC lifted its holdings in IDEXX Laboratories by 3.3% in the fourth quarter. Summit Trail Advisors LLC now owns 810 shares of the company's stock worth $335,000 after acquiring an additional 26 shares during the last quarter. Finally, Forum Financial Management LP lifted its holdings in IDEXX Laboratories by 4.9% in the fourth quarter. Forum Financial Management LP now owns 621 shares of the company's stock worth $257,000 after acquiring an additional 29 shares during the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Trading Down 0.6%

NASDAQ IDXX traded down $3.03 on Friday, hitting $512.52. 1,221,827 shares of the stock were exchanged, compared to its average volume of 652,599. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $530.60. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The company has a market capitalization of $41.22 billion, a price-to-earnings ratio of 48.03, a P/E/G ratio of 3.41 and a beta of 1.52. The company's 50-day moving average price is $449.80 and its two-hundred day moving average price is $437.41.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The firm had revenue of $998.43 million for the quarter, compared to analysts' expectations of $998.25 million. During the same period in the previous year, the company posted $2.71 EPS. The company's quarterly revenue was up 3.6% compared to the same quarter last year. Research analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insider Activity

In other news, Director M Anne Szostak sold 1,260 shares of the business's stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total transaction of $645,548.40. Following the transaction, the director now directly owns 1,801 shares in the company, valued at $922,724.34. The trade was a 41.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.98% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

IDXX has been the topic of a number of recent research reports. Wall Street Zen cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Friday. Piper Sandler lifted their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a report on Monday, February 10th. Stifel Nicolaus lifted their price target on IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a report on Monday, May 19th. Bank of America lifted their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a report on Tuesday, February 4th. Finally, Morgan Stanley boosted their target price on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a report on Monday, May 5th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $536.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.